Incyte Corporation $INCY reported FYQ3 results. For the quarter, EPS was $0.19, beating the guidance by $0.20. Revenue was $269.47 million, a 43% growth Y-o-Y; and beating the guidance by $8.04 million. Revenue growth was mainly driven by strong sales of Jakafi (ruxolitinib) in the U.S., Iclusig (ponatinib) in Europe and royalties from ex-U.S. sales of Jakavi (ruxolitinib) by Novartis.